CytomX Accounts Payable vs Common Stock Analysis
CTMX Stock | USD 1.96 0.02 1.03% |
CytomX Therapeutics financial indicator trend analysis is way more than just evaluating CytomX Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CytomX Therapeutics is a good investment. Please check the relationship between CytomX Therapeutics Accounts Payable and its Common Stock accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.
Accounts Payable vs Common Stock
Accounts Payable vs Common Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CytomX Therapeutics Accounts Payable account and Common Stock. At this time, the significance of the direction appears to have almost no relationship.
The correlation between CytomX Therapeutics' Accounts Payable and Common Stock is 0.12. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Common Stock in the same time period over historical financial statements of CytomX Therapeutics, assuming nothing else is changed. The correlation between historical values of CytomX Therapeutics' Accounts Payable and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of CytomX Therapeutics are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Accounts Payable i.e., CytomX Therapeutics' Accounts Payable and Common Stock go up and down completely randomly.
Correlation Coefficient | 0.12 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Accounts Payable
An accounting item on the balance sheet that represents CytomX Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of CytomX Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Common Stock
Most indicators from CytomX Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CytomX Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.Tax Provision is likely to rise to about 3 M in 2024, whereas Selling General Administrative is likely to drop slightly above 28.8 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 69.6M | 53.2M | 99.0M | 53.9M | Total Revenue | 69.6M | 53.2M | 101.2M | 54.2M |
CytomX Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
CytomX Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CytomX Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 341.3M | 358.7M | 339.4M | 260.9M | 205.2M | 284.4M | |
Other Current Liab | 27.2M | 19.9M | 30.6M | 24.5M | 17.6M | 17.9M | |
Total Current Liabilities | 85.6M | 100.9M | 106.3M | 152.6M | 155.9M | 82.7M | |
Total Stockholder Equity | 51.1M | 49.8M | 89.4M | (85.8M) | (47.4M) | (45.1M) | |
Other Liab | 179.7M | 186.3M | 125.7M | 180.1M | 207.1M | 151.2M | |
Property Plant And Equipment Net | 32.8M | 29.4M | 25.3M | 21.0M | 16.2M | 14.9M | |
Current Deferred Revenue | 51.4M | 74.9M | 69.3M | 121.3M | 132.3M | 138.9M | |
Net Debt | (163.6M) | (167.0M) | (187.5M) | (175.6M) | (3.2M) | (3.4M) | |
Retained Earnings | (417.2M) | (450.1M) | (533.7M) | (722.9M) | (723.4M) | (687.3M) | |
Accounts Payable | 4.2M | 3.0M | 2.8M | 2.8M | 1.5M | 2.7M | |
Cash | 188.4M | 191.9M | 205.5M | 193.7M | 17.2M | 16.3M | |
Non Current Assets Total | 37.9M | 34.7M | 29.1M | 23.8M | 22.2M | 19.8M | |
Non Currrent Assets Other | 2.9M | (3.4M) | (3.7M) | (3.6M) | 83K | 78.9K | |
Other Assets | 2.9M | 25.6M | 1.8M | 944K | 1.1M | 1.0M | |
Cash And Short Term Investments | 296.1M | 316.1M | 305.2M | 193.7M | 174.5M | 253.8M | |
Net Receivables | 13K | 798K | 790K | 36.0M | 3.4M | 5.6M | |
Common Stock Shares Outstanding | 45.3M | 46.1M | 64.1M | 65.7M | 73.8M | 48.9M | |
Short Term Investments | 188.6M | 107.7M | 124.3M | 99.7M | 157.3M | 117.8M | |
Liabilities And Stockholders Equity | 341.3M | 358.7M | 339.4M | 260.9M | 205.2M | 284.4M | |
Non Current Liabilities Total | 204.6M | 207.9M | 143.7M | 194.0M | 96.7M | 167.7M | |
Other Current Assets | 7.2M | 7.1M | 4.3M | 7.5M | 5.0M | 5.2M | |
Other Stockholder Equity | 468.3M | 500.0M | 623.3M | 637.1M | 675.9M | 709.7M | |
Total Liab | 290.2M | 308.9M | 250.0M | 346.6M | 252.6M | 250.4M | |
Property Plant And Equipment Gross | 32.8M | 29.4M | 25.3M | 21.0M | 30.9M | 16.4M | |
Total Current Assets | 303.3M | 324.0M | 310.3M | 237.1M | 182.9M | 264.6M | |
Accumulated Other Comprehensive Income | 57K | (47K) | (242K) | 10K | 95K | 99.8K | |
Short Term Debt | 2.8M | 3.2M | 3.6M | 4.1M | 4.6M | 4.7M | |
Intangible Assets | 1.3M | 1.2M | 1.0M | 875K | 729K | 1.1M | |
Property Plant Equipment | 6.9M | 32.8M | 7.0M | 6.0M | 6.9M | 8.3M | |
Net Tangible Assets | 48.9M | 47.7M | 87.4M | (2.4M) | (2.8M) | (2.7M) | |
Retained Earnings Total Equity | (417.2M) | (450.1M) | (533.7M) | (623.6M) | (561.2M) | (533.1M) | |
Capital Surpluse | 446.0M | 468.3M | 500.0M | 623.3M | 716.8M | 474.2M | |
Non Current Liabilities Other | 850K | 207.9M | 143.7M | 262M | 3.9M | 3.7M | |
Net Invested Capital | 51.1M | 49.8M | 89.4M | (85.8M) | (47.4M) | (45.1M) | |
Net Working Capital | 217.7M | 223.1M | 204.0M | 84.5M | 27.0M | 25.7M |
Pair Trading with CytomX Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CytomX Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytomX Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to CytomX Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CytomX Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CytomX Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CytomX Therapeutics to buy it.
The correlation of CytomX Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CytomX Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CytomX Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CytomX Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for CytomX Stock analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is CytomX Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.21 | Revenue Per Share 1.533 | Quarterly Revenue Growth 0.764 | Return On Assets 0.0323 | Return On Equity (54.75) |
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.